AI Engines For more Details: Perplexity Kagi Labs You
Antispasmodic Action: Methylatropine nitrate acts as an antimuscarinic agent, meaning it blocks the action of acetylcholine at muscarinic receptors. By doing so, it inhibits the involuntary contractions of smooth muscles, particularly in the GI tract and the urinary system. This action helps to relieve spasms and cramps in these organs.
Gastrointestinal Disorders: Methylatropine nitrate is commonly used to alleviate symptoms associated with gastrointestinal disorders such as irritable bowel syndrome (IBS), gastric ulcers, diverticulitis, and other conditions characterized by spasms or cramps in the GI tract. It can help reduce abdominal pain, bloating, and discomfort.
Urinary Disorders: Methylatropine nitrate may also be used to treat urinary disorders characterized by involuntary muscle contractions, such as overactive bladder or urinary incontinence. By reducing bladder spasms, it can help improve urinary control and reduce urgency and frequency of urination.
Preoperative Medication: Methylatropine nitrate is sometimes administered before surgery to reduce secretions in the respiratory and GI tracts. By drying up these secretions, it can help prevent complications such as aspiration pneumonia during anesthesia.
Adjunctive Therapy: In some cases, methylatropine nitrate may be used as adjunctive therapy in the treatment of certain medical conditions, particularly those involving spasms or hypersecretion.
Side Effects: Like all medications, methylatropine nitrate may cause side effects. Common side effects may include:
Contraindications: Methylatropine nitrate is contraindicated in individuals with a known hypersensitivity to the medication or its components. It should also be used with caution in patients with certain medical conditions such as glaucoma, prostatic hypertrophy, or obstructive urinary disorders.
Dosage and Administration: The dosage of methylatropine nitrate is individualized based on the patient's condition and response to treatment. It is typically administered orally in the form of tablets or as an injection for intramuscular or intravenous use.
Monitoring: Patients taking methylatropine nitrate should be monitored for adverse effects, particularly those related to anticholinergic activity such as dry mouth, urinary retention, and constipation. Dosage adjustments may be necessary based on the patient's response and tolerance to the medication.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.3 | 0.3 | 0 |
| Allergic Rhinitis (Hay Fever) | 0.6 | 0.4 | 0.5 |
| Allergies | 1.3 | 0.6 | 1.17 |
| Allergy to milk products | 1 | 0.6 | 0.67 |
| Alzheimer's disease | 0.9 | 1.6 | -0.78 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1 | 0.7 | 0.43 |
| Ankylosing spondylitis | 1.3 | 0.6 | 1.17 |
| Anorexia Nervosa | 0.3 | 0.6 | -1 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
| Asthma | 0.7 | 0.7 | |
| Atherosclerosis | 0.7 | 0.7 | |
| Atrial fibrillation | 0.9 | 0.6 | 0.5 |
| Autism | 1.3 | 2 | -0.54 |
| Autoimmune Disease | 0.6 | 0.6 | |
| benign prostatic hyperplasia | 0.6 | 0.6 | |
| Biofilm | 0.4 | 0.4 | |
| Bipolar Disorder | 0.9 | 0.6 | 0.5 |
| Brain Trauma | 0.3 | -0.3 | |
| Breast Cancer | 0.4 | 0.4 | |
| Carcinoma | 0.9 | 0.3 | 2 |
| Celiac Disease | 0.4 | 0.6 | -0.5 |
| Cerebral Palsy | 0.3 | -0.3 | |
| Chronic Fatigue Syndrome | 1 | 0.7 | 0.43 |
| Chronic Kidney Disease | 0.7 | 0.7 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.7 | 0.6 | 0.17 |
| Chronic Urticaria (Hives) | 1 | 1 | |
| Coagulation / Micro clot triggering bacteria | 1 | 0.3 | 2.33 |
| Cognitive Function | 0.3 | 0.3 | |
| Colorectal Cancer | 1.6 | 0.4 | 3 |
| Constipation | 1.2 | 1.2 | |
| Coronary artery disease | 1.3 | 0.3 | 3.33 |
| COVID-19 | 1.3 | 0.9 | 0.44 |
| Crohn's Disease | 1.6 | 1 | 0.6 |
| cystic fibrosis | 1 | 1 | |
| d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
| deep vein thrombosis | 1.3 | 0.3 | 3.33 |
| Depression | 1.9 | 1.6 | 0.19 |
| Eczema | 0.6 | 0.6 | |
| Endometriosis | 1.3 | 1.3 | 0 |
| Epilepsy | 1 | 1 | |
| erectile dysfunction | 0.6 | 0.6 | |
| Fibromyalgia | 0.1 | -0.1 | |
| Functional constipation / chronic idiopathic constipation | 1.9 | 0.7 | 1.71 |
| gallstone disease (gsd) | 1.3 | 1.3 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | -0.3 | |
| Generalized anxiety disorder | 1.3 | 0.3 | 3.33 |
| Gout | 0.3 | 0.3 | 0 |
| Graves' disease | 0.3 | 0.6 | -1 |
| Gulf War Syndrome | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.4 | 0.4 | 0 |
| Heart Failure | 1.7 | 0.3 | 4.67 |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| High Histamine/low DAO | 0.4 | 0.3 | 0.33 |
| hypercholesterolemia (High Cholesterol) | 0.4 | 0.4 | |
| hyperglycemia | 1 | 1 | |
| hypertension (High Blood Pressure | 1.3 | 0.7 | 0.86 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 1 | 1 | |
| IgA nephropathy (IgAN) | 0.3 | 0.1 | 2 |
| Inflammatory Bowel Disease | 1 | 1.5 | -0.5 |
| Insomnia | 0.3 | 0.6 | -1 |
| Intelligence | 0.7 | 0.7 | |
| Intracranial aneurysms | 0.3 | 0.3 | 0 |
| Irritable Bowel Syndrome | 1.4 | 0.9 | 0.56 |
| ischemic stroke | 0.7 | 0.6 | 0.17 |
| Liver Cirrhosis | 1.6 | 1 | 0.6 |
| Long COVID | 1 | 1.2 | -0.2 |
| Low bone mineral density | 0.6 | -0.6 | |
| Lung Cancer | 0.6 | 0.3 | 1 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.6 | 0.6 | 0 |
| ME/CFS with IBS | 0.1 | -0.1 | |
| Metabolic Syndrome | 1.6 | 0.6 | 1.67 |
| Mood Disorders | 1.5 | 1.6 | -0.07 |
| Multiple Sclerosis | 0.9 | 0.7 | 0.29 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| myasthenia gravis | 0.6 | 0.6 | |
| neuropathic pain | 0.3 | -0.3 | |
| Neuropathy (all types) | 0.6 | -0.6 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.6 | 0.9 | 0.78 |
| Obesity | 2 | 0.9 | 1.22 |
| obsessive-compulsive disorder | 1.5 | 0.4 | 2.75 |
| Osteoarthritis | 0.6 | 0.3 | 1 |
| Osteoporosis | 0.9 | 0.9 | |
| Parkinson's Disease | 1.7 | 1.5 | 0.13 |
| Polycystic ovary syndrome | 1.4 | 0.6 | 1.33 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Primary sclerosing cholangitis | 0.6 | -0.6 | |
| Psoriasis | 0.7 | 0.3 | 1.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.7 | 0.3 | 4.67 |
| Rosacea | 0.4 | 0.4 | |
| Schizophrenia | 0.9 | 0.9 | 0 |
| scoliosis | 0.7 | 0.4 | 0.75 |
| Sjögren syndrome | 0.6 | 0.6 | |
| Sleep Apnea | 0.9 | 0.6 | 0.5 |
| Slow gastric motility / Gastroparesis | 0.7 | 0.7 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 0.7 | |
| Stress / posttraumatic stress disorder | 0.4 | 0.3 | 0.33 |
| Systemic Lupus Erythematosus | 0.9 | 0.6 | 0.5 |
| Tic Disorder | 0.3 | 0.3 | |
| Type 1 Diabetes | 1.2 | 0.6 | 1 |
| Type 2 Diabetes | 1.6 | 1 | 0.6 |
| Ulcerative colitis | 1.3 | 0.6 | 1.17 |
| Unhealthy Ageing | 0.4 | 0.3 | 0.33 |
| Vitiligo | 0.6 | 0.1 | 5 |
